Chronic Conditions, Polypharmacy & Ethical Prescribing

 Using Salomon et al. (2021) and Prasher & Janicki Ch. 16, discuss: (1) What are the most pressing risks of polypharmacy in this population? (2) How should interdisciplinary teams navigate ethical tensions between behavioral control, quality of life, and informed consent for individuals who may have limited capacity to self-advocate? (3) How could a free AI tool like Microsoft Copilot or Google Gemini help monitor medication interactions—and what risks would it introduce?